1. Scrip
  2. >>Focus On Asia

Sanpower Reconstructs Dendreon Deal To Drive Better Growth

 
• By Ying Huang

Sanpower Group is planning the first Asian launch of Provenge in Hong Kong after acquiring a local cell therapy manufacturing facility, amid the ongoing sale of Dendreon to its public holding company Nanjing Cenbest, the latest deal in the surge of traditional companies breaking into the healthcare sector in China.

Coins

Five months after completing the acquisition of Dendreon Corp., Chinese conglomerate Sanpower Group has taken a substantial step toward making real progress with the heart of the deal, Provenge (sipuleucel-T), as it is preparing to file the drug registration with the Pharmacy and Poisons Board of Hong Kong, the first move to advance the immunotherapy’s development in Asia.

Through a Hong Kong entity, Dendreon HK Limited, Sanpower finished the acquisition of a manufacturing facility in Wong Chuk Hang...

More from China

More from Focus On Asia

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?